Compare UONE & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UONE | NEPH |
|---|---|---|
| Founded | 1980 | 1997 |
| Country | United States | United States |
| Employees | 1396 | N/A |
| Industry | Broadcasting | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 31.0M |
| IPO Year | N/A | 2004 |
| Metric | UONE | NEPH |
|---|---|---|
| Price | $6.23 | $2.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 47.6K | 20.8K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1000.00 |
| EPS | N/A | ★ 0.11 |
| Revenue | N/A | ★ $18,789,000.00 |
| Revenue This Year | N/A | $11.24 |
| Revenue Next Year | N/A | $11.58 |
| P/E Ratio | ★ N/A | $26.82 |
| Revenue Growth | N/A | ★ 32.67 |
| 52 Week Low | $0.86 | $1.78 |
| 52 Week High | $16.94 | $6.42 |
| Indicator | UONE | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 45.73 | 44.51 |
| Support Level | $5.26 | $2.79 |
| Resistance Level | $7.62 | $3.21 |
| Average True Range (ATR) | 0.56 | 0.17 |
| MACD | 0.19 | 0.05 |
| Stochastic Oscillator | 78.47 | 65.47 |
Urban One Inc is an urban oriented, multi-media company. Its business is radio broadcasting franchise that is the radio broadcasting operation that targets African-American and urban listeners. It operates through the following segments: Radio Broadcasting, Reach Media, Digital, and Cable Television. The Radio Broadcasting segment includes all the broadcasting related operations. The Reach Media segment consists of the Tom Joyner Morning Show and its related activities. The Digital segment focuses on its online business, including the operations of Interactive One. The Cable Television segment deals with TV One's operations.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.